Tambotatug pelitecan not checked
MediLink Therapeutics (Suzhou) Co., Ltd. · YL201
FollowEvery change as it happens, and a Monday email
Trials
12 active
12 in total · 2 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.”In the company’s words, NCT06629597 on ClinicalTrials.gov
- Tested for
- Small Cell Lung Cancer (2 trials), Advanced Solid Tumor (2 trials), Advanced Solid Tumors (2 trials), Nasopharyngeal Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), SCLC, Extensive Stage and 4 more
- Main trialPhase 3
- “This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.”In the company’s words, NCT06629597 on ClinicalTrials.gov
- Other names
- YL201 · Tam-Peli
Other drugs for Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
- MHB088CQilu Pharmaceutical · Phase 3
Coming up11
- Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 6 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 29 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 1 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Nov 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Jan 2029Phase 3 trial completes · ClinicalTrials.gov
- Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Dec 2027 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | |
| Phase 3Active, not recruiting | 1 Dec 2027 | A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) | |
| Phase 3Recruiting | 30 Apr 2028 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | |
| Phase 3Not yet recruiting | Jan 2029 | A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy | |
| Phase 3Recruiting | Jun 2029 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | |
| Phase 2Recruiting | Feb 2027 | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | |
| Phase 1/2Active, not recruiting | Oct 2026 | A Study YL201 in Patients With Selected Advanced Solid Tumors | |
| Phase 1/2Recruiting | Jan 2027 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | |
| Phase 1/2Recruiting | 6 Apr 2027 | A Study of YL201 in Patients With Advanced Solid Tumors | |
| Phase 1/2Recruiting | Feb 2028 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | |
| Phase 1/2Recruiting | Nov 2028 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | |
| Phase 1Active, not recruiting | 29 Apr 2027 | A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026